Medacta Beats Profit Forecasts, Raises Growth Guidance

Core Financial Highlights

Medacta (SIX:MOVE) reported strong full-year financial results, with adjusted EBITDA of €191 million, surpassing consensus estimates by 1 percent. The figure was driven by cost savings in sales and marketing.

The adjusted EBITDA margin reached 27.9 percent for the year, or 29 percent in constant currencies, despite negative impacts from foreign exchange headwinds on gross profit margins.

Operational Performance and Cash Flow

The medical device company demonstrated robust cash flow, with operating cash flow increasing by 42.5 percent to €152.7 million. Free cash flow also improved to €15.7 million.

Significant capital expenditure of €137.0 million was directed toward growth initiatives, primarily for surgical instruments and the expansion of production facilities.

Future Outlook and Shareholder Value

Looking ahead, Medacta issued fiscal year 2026 guidance for 10 to 14 percent growth in constant currency. The company also upgraded its midterm guidance to a new range of 12 to 15 percent.

In a move beneficial to shareholders, the announced dividend came in 12 percent ahead of analyst expectations, reflecting confidence in the company's financial health.

Summary and Market Outlook

Medacta's performance highlights effective cost management and a strong focus on strategic growth investments. The upgraded guidance and higher dividend signal a positive outlook, positioning the company for continued expansion despite external currency pressures.

FAQ

Q: What was Medacta's adjusted EBITDA for the full year?
A: The company reported an adjusted EBITDA of €191 million, with a margin of 27.9 percent.

Q: What is Medacta's new midterm growth guidance?
A: The company raised its midterm guidance to a range of 12 to 15 percent growth.

Q: How did foreign exchange affect Medacta's results?
A: Foreign exchange movements negatively impacted the company's gross profit margins.

Source: Investing.com